Universal Biosensors Inc
ASX:UBI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Universal Biosensors Inc
Net Income (Common)
Universal Biosensors Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
Universal Biosensors Inc
ASX:UBI
|
Net Income (Common)
-AU$17.5m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-10%
|
|
|
Somnomed Ltd
ASX:SOM
|
Net Income (Common)
-AU$2.6m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Cochlear Ltd
ASX:COH
|
Net Income (Common)
AU$345.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
7%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Net Income (Common)
-AU$7.3m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
-19%
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Net Income (Common)
AU$7.8m
|
CAGR 3-Years
52%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Net Income (Common)
-AU$10.2m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Universal Biosensors Inc
Glance View
Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, COVID-19, women’s health and fertility, non-human and environmental testing using its patented platform technology and hand-held point of use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates a proprietary electrochemical sensing system using opposing electrodes that detects specific analytes in samples as small as a droplet. Its products include Sentia, a wine analyzer, and Xprecia Prime, a coagulation analyzer. Its Hemostasis Reference Laboratory Meso Scale Discovery (MSD) multiplex platform couples immunoassay methodology with electrochemiluminescence (ECL) detection to provide measurement of a multitude of different cytokine panels. Its laboratory services include assay validation and analysis and consultation for study design.
See Also
What is Universal Biosensors Inc's Net Income (Common)?
Net Income (Common)
-17.5m
AUD
Based on the financial report for Jun 30, 2025, Universal Biosensors Inc's Net Income (Common) amounts to -17.5m AUD.
What is Universal Biosensors Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-10%
Over the last year, the Net Income (Common) growth was -51%. The average annual Net Income (Common) growth rates for Universal Biosensors Inc have been -2% over the past three years , -24% over the past five years , and -10% over the past ten years .
